



Published on *British Columbia Drug and Poison Information Centre (BC DPIC)* (<http://www.dpic.org>)

[Home](#) > [Drug Product Listings](#) > [Eribulin](#) > [Printer-friendly PDF](#)

Eribulin

Trade Name:

Halaven

Manufacturer/Distributor:

Eisai Limited

ca.eisai.com

Classification:

Antineoplastic agent

ATC Class:

L01XX41

Status:

active

Notice of Compliance (yyyy/mm/dd):

2011/12/14

Date Marketed in Canada (yyyy/mm/dd):

2012/03/10

Presentation:

Injection: 0.5 mg/mL. DIN: 02377438

Comments:

For treatment of metastatic breast cancer in patients who have had at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxine.

Keywords: eribulin

breast neoplasms

Access:

public

All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is *not* meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this site is governed and restricted by specific terms of use. Please review the **full terms and conditions** below prior to using the DPIC website. In the event of a poisoning emergency, call your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases.

Terms and Conditions

Source URL (retrieved on 2019-09-23 06:42): <http://www.dpic.org/druglisting/eribulin>